Cheung et al. describe efficient T cell control of nascent neoantigen+ and nearby neoantigen-negative sarcoma cells, underlying a ∼50% reduction in tumor penetrance. This otherwise imperceptible immun...

Dalit, Tan and colleagues provide a multiomic profile of T follicular helper (TFH) cells responses to diverse pathogens, revealing a blueprint for transcriptional flexibility and new tools to interrog...

Persistent antigen stimulation promotes differentiation of exhausted CD8+ T (TEX) cells. TEX cells are distinct from circulating memory T (TCIRCM) cells but share many features with tissue-resident me...

ICOS agonists are being investigated for cancer immunotherapy based on the idea that they will reinvigorate exhausted CD8+ T cell anti-cancer immunity. Humblin et al. unexpectedly find the opposite—th...

Understanding regulation of progenitor exhausted CD8+ T (Tpex) cell differentiation is important for immunotherapies. Humblin et al. report that sustained ICOS costimulation is detrimental to PD-1+CD8+ T cell responses. Limiting ICOS signaling enhances Tpex cell stemness and differentiation into effector-like cells with improved survival and functionality. ICOSL blockade reinvigorates PD-1+CD8+ T cells and promotes viral or tumor control, potentiating PD-1 targeted immunotherapy.

Peter Mac is recruiting a Group Leader to increase the capacity and efficiency of our “discovery to translation” cancer research pipeline.

Group Leader

ID3 defines stem-like T cells with high developmental potential that sustain T cell responses to chronic infection and cancer.

Postdoctoral Researcher - Eckersley Maslin Lab

T cell therapies for cancer currently rely on extensive in vitro expansion in hypermetabolic conditions. Frisch et al. demonstrate that T cells grown in vitro perform extensive aerobic glycolysis. Rer...

The metabolic landscape of cancer greatly influences antitumor immunity, yet it remains unclear how organ-specific metabolites in the tumor microenvironment influence immunosurveillance. We found that...

ACLY-deficient CAR T cells targeting the tumor-associated antigen disialoganglioside GD2 (GD2 CAR T cells) also resisted acquiring TEX-like properties, exhibiting reduced CD39 expression when co-cultu...